Pharmacoeconomics

PharmacoEconomics is a peer-reviewed hybrid journal published by Adis International, part of Springer Nature, founded in 1992 and dedicated to the practical application of health economics and outcomes research to healthcare resource allocation, with a 2025 Journal Impact Factor of 4.7《药物经济学》是由（Adis International，Springer Nature）出版的同行评审混合期刊，1992 年创刊，致力于将卫生经济学与结果研究应用于医疗资源配置，2025 年影响因子为 4.7。

Scope

• The journal communicates complex pharmacoeconomic issues related to all healthcare interventions, including drugs, diagnostics, devices, personalized medicine and surgical interventions期刊传播与各类医疗干预相关的复杂药物经济学议题，包括药物、诊断、器械、个性化医疗与外科干预。
• Applied health economics and outcomes research aimed at optimizing healthcare resource allocation is its central subject以优化医疗资源配置为目标的应用卫生经济学与结果研究是其核心主题。
• It serves clinicians, professionals involved in health technology assessment and those concerned with healthcare budgeting and prescribing decisions期刊服务临床医生、参与卫生技术评估的专业人员以及关注医疗预算与处方决策的群体。
• Cost-effectiveness analysis, budget impact analysis, discrete choice experiments and utility measurement are among the methods regularly represented成本效果分析、预算影响分析、离散选择实验与效用测量是期刊中常见的代表性方法。
• Economic evaluation of gene and cell therapies, equity in health technology assessment and obesity-related economic burden are current thematic priorities基因与细胞疗法的经济学评价、卫生技术评估中的公平性以及肥胖相关经济负担是当前的主题重点。
• Article types include original research, authoritative reviews, practical applications and commentaries on methodological and policy questions文章类型包括原创研究、权威综述、实践应用以及针对方法学与政策问题的评论。
• Each article is accompanied by a Key Points summary, and plain-language summaries and digital features such as video abstracts and infographics are peer reviewed to the same standard as the article每篇文章附有要点摘要，通俗语言摘要与视频摘要、信息图等数字功能也与正文接受同等标准的同行评审。

History

• PharmacoEconomics was founded in 1992 by Adis International in Auckland, New Zealand, and it remains an Adis title within Springer Nature《药物经济学》于 1992 年由新西兰奥克兰的（Adis International）创办，如今仍是（Springer Nature）旗下的（Adis）期刊。
• It has appeared monthly for most of its history and now publishes twelve issues a year期刊历史上大部分时间按月出版，现每年出版 12 期。
• Its print ISSN is 1170-7690 and its electronic ISSN is 1179-2027其印刷刊号为 1170-7690，电子刊号为 1179-2027。
• It is a hybrid journal, charging no author fee on the traditional subscription route while offering open access under Springer Open Choice when authors or funders require it期刊为混合模式，传统订阅路径不向作者收费，当作者或资助方要求时可通过（Springer Open Choice）开放获取。
• The 2025 Journal Impact Factor is 4.7 and the five-year impact factor is 6.0, with a median of seven days from submission to first decision2025 年影响因子为 4.7，五年影响因子为 6.0，投稿至首次决定的中位时间为 7 天。
• It is indexed in Science Citation Index Expanded, the Social Science Citation Index, MEDLINE, EMBASE, Scopus and RePEc期刊被（Science Citation Index Expanded）、（Social Science Citation Index）、（MEDLINE）、（EMBASE）、（Scopus）与（RePEc）收录。
• The journal drew 1.2 million downloads in 2025, reflecting its use by health technology assessment agencies and payers worldwide2025 年期刊下载量达 120 万次，反映其被全球卫生技术评估机构与支付方使用。

Editors

• The journal is edited by Christopher I. Carswell and Timothy Wrightson, both of Adis International期刊由（Adis International）的（Christopher I. Carswell）与（Timothy Wrightson）共同主编。
• Carswell, who holds a master's degree in pharmacy, also serves as the journal's contact for pre-submission enquiries拥有药学硕士学位的（Carswell）同时担任期刊投稿前咨询的联系人。
• An international editorial board includes researchers from the United States, the United Kingdom, Canada, Australia, the Netherlands, Spain, Italy, Germany, China and elsewhere国际编委会包括来自美国、英国、加拿大、澳大利亚、荷兰、西班牙、意大利、德国、中国等地的研究者。
• Peer review is conducted through Editorial Manager and draws on a database of international experts shared with other Adis journals同行评审经（Editorial Manager）进行，并使用与其他（Adis）期刊共享的国际专家数据库。
• Pre-submission enquiries are welcomed for proposals, and the journal runs themed collections and calls for papers on emerging topics期刊欢迎就选题进行投稿前咨询，并围绕新兴主题组织专题文集与征稿。
• The editorial team emphasises clear communication of methods and results so that decision makers can act on published economic evidence编辑团队强调方法与结果的清晰表达，以便决策者能依据已发表的经济学证据采取行动。